MARKET WIRE NEWS

Subscribe to Our Newsletter

Vir Biotechnology Announces PSMA-targeted PRO-XTEN® Dual-masked T-cell Engager VIR-5500 Received FDA Fast Track Designation for the Treatment of Prostate Cancer

MWN-AI** Summary

Vir Biotechnology, Inc. (Nasdaq: VIR) has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for its investigational drug, VIR-5500. This PSMA-targeted PRO-XTEN® dual-masked T-cell engager is designed to treat late-line metastatic castration-resistant prostate cancer (mCRPC). The drug is being co-developed with Astellas Pharma Inc., highlighting its potential to meet a critical need in the prostate cancer treatment landscape.

The Fast Track designation is meant to expedite the development and review process for therapies addressing serious conditions with unmet needs. Marianne De Backer, CEO of Vir Biotechnology, emphasized the urgency of advancing VIR-5500, with pivotal Phase 3 trials slated to begin in 2027. The collaboration with Astellas aims to make a significant difference for patients and their families struggling with advanced prostate cancer.

VIR-5500 is currently undergoing evaluation in Phase 1 clinical studies across six different dose-expansion cohorts. These cohorts include various treatment-experienced and treatment-naïve mCRPC patients, assessing the safety and efficacy of the drug both as a monotherapy and in combination with existing therapies, such as enzalutamide and docetaxel. Early data suggests that VIR-5500 is generally well-tolerated and may show promising anti-tumor activity.

The PRO-XTEN® technology behind VIR-5500 is crucial for its mechanism, as it activates T-cells specifically within the tumor microenvironment, aiming to reduce systemic toxicity and enhance overall therapeutic efficacy. This innovative approach could provide advanced prostate cancer patients with new, effective options to improve their quality of life and long-term disease control.

MWN-AI** Analysis

Vir Biotechnology's announcement regarding the FDA's Fast Track designation for its PSMA-targeted PRO-XTEN® dual-masked T-cell engager, VIR-5500, marks a significant development in the biopharmaceutical sector, particularly in the treatment of late-line metastatic castration-resistant prostate cancer (mCRPC). This designation not only underscores the unmet medical need in this patient population but also enhances the visibility and potential investment value of Vir Biotechnology.

From a market perspective, investors should consider several factors. First, the collaboration with Astellas Pharma, a well-established player in oncology, provides strategic advantages in resource sharing and expertise. This partnership can enhance the credibility of the clinical trials and can lead to a streamlined path towards commercialization if the Phase 3 trials, projected to commence in 2027, yield positive results.

Given that the pipeline data released earlier indicated that VIR-5500 is generally well tolerated and exhibits promising anti-tumor activity, this positions Vir Biotechnology favorably. Investors should closely monitor upcoming trial phases, especially data readouts, as they will significantly influence stock performance.

Additionally, as the prostate cancer market is projected to grow, the importance of innovative therapies combining safety and efficacy is paramount. By leveraging the PRO-XTEN® masking technology, which aims to deliver targeted action while minimizing side effects, Vir could appeal to a broader range of oncologists and patients seeking effective treatment options.

Nevertheless, potential investors must also acknowledge the risks associated with drug development, including the challenges that may arise from unexpected safety or efficacy outcomes. Thus, a cautious but optimistic approach is advisable. Continuous assessment of clinical progress, regulatory interactions, and competitive dynamics will be crucial in shaping future investment decisions in Vir Biotechnology.

**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.

Source: Business Wire

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to VIR-5500, a PSMA-targeted PRO-XTEN ® dual-masked T-cell engager (TCE), for the treatment of late-line metastatic castration-resistant prostate cancer (mCRPC). VIR-5500 is being co-developed by Astellas Pharma Inc. and Vir Biotechnology through a global strategic collaboration.

“Receiving Fast Track designation reflects the potential of VIR-5500 to address an area of serious unmet need in late-line mCRPC and the strong momentum we have achieved with Astellas as we prepare to enter pivotal Phase 3 development in 2027,” said Marianne De Backer, President and Chief Executive Officer of Vir Biotechnology. “We look forward to working with the FDA to rapidly advance the development of VIR-5500 for people living with mCRPC.”

“People living with advanced prostate cancer need new treatment options that can offer meaningful and durable benefit,” said Moitreyee Chatterjee-Kishore, Executive Vice President and Head of Oncology Development, Astellas. “This Fast Track designation reinforces the importance of advancing VIR-5500 with urgency, and we are committed to exploring its potential to make a meaningful difference for patients and their families.”

FDA Fast Track designation is intended to facilitate and expedite the development and review of drugs to treat serious conditions and fill an unmet need.

VIR-5500 is being evaluated in a Phase 1 study across six dose-expansion cohorts. The monotherapy dose-expansion cohorts include patients with taxane naïve mCRPC, radioligand therapy naïve mCRPC and radioligand therapy exposed mCRPC. The combination regimen dose-expansion cohorts include VIR-5500 in combination with enzalutamide in early-line mCRPC, VIR-5500 in combination with docetaxel in early-line mCRPC and VIR-5500 in combination with darolutamide in metastatic hormone sensitive prostate cancer (mHSPC). Phase 1 data reported earlier this year showed VIR-5500 was generally well tolerated and exhibited promising anti-tumor activity in patients with mCRPC. Phase 3 trials are anticipated to begin in 2027.

About VIR-5500

T-cell engagers (TCEs) are powerful anti-tumor agents that can direct the immune system, specifically T-cells, to destroy cancer cells. VIR-5500 is an investigational PRO-XTEN ® dual-masked TCE currently being evaluated in an open-label, non-randomized Phase 1 clinical trial ( NCT05997615 ) designed to assess the safety, pharmacokinetics and preliminary efficacy in participants with metastatic castration-resistant prostate cancer (mCRPC).

VIR-5500 combines a bispecific PSMA and CD3 binding TCE with the PRO-XTEN ® masking technology. The PRO-XTEN ® masking technology is designed to keep the TCEs inactive (or masked) until they reach the tumor microenvironment, where tumor-specific proteases cleave off the mask and activate the TCEs, enabling killing of cancer cells by T-cells. By confining the activity to the tumor microenvironment, we aim to circumvent the traditionally high toxicity associated with unmasked TCEs and increase their efficacy and tolerability. Additionally, the mask is designed to help drug candidates stay in the bloodstream longer in their inactive form, allowing them to better reach the site of action and potentially allowing for less frequent dosing regimens .

About PRO-XTEN ® Dual-masked T-cell Engagers (TCEs)

T-cell engagers (TCEs) are powerful anti-tumor agents designed to direct the immune system, specifically T-cells, to destroy cancer cells. TCEs have become an important treatment option for blood cancers, but their usage in solid tumors has been limited due to toxicity. The universal PRO-XTEN ® masking technology is designed to extend the half-life of the molecule and to keep TCEs inactive (or masked) until they reach the tumor microenvironment, where tumor-specific proteases cleave off the mask and activate the TCEs, leading to killing of cancer cells by T-cells. By extending the half-life and confining activity to the tumor microenvironment, the PRO-XTEN ® technology could limit toxicity, widen the therapeutic index of TCEs, and potentially enable less frequent dosing regimens.

About Advanced Prostate Cancer

Prostate cancer remains a significant global health burden, representing the second leading cause of cancer-related mortality in men behind lung cancer. 1 While diagnostic and therapeutic advances like androgen-directed therapy can improve outcomes in earlier settings, most patients ultimately relapse and develop metastatic hormone sensitive prostate cancer (mHSPC). 2 mHSPC is characterized by its responsiveness to intensified hormonal interventions designed to reduce androgen levels or block their action. The majority of these patients eventually progress to metastatic castration-resistant prostate cancer (mCRPC). 3 This stage is associated with poor clinical outcomes, including limited durability of existing therapies, with a 5-year survival rate of approximately 30%. 4 There is a critical need for safer, more effective and precisely targeted therapies capable of improving long term disease control and quality of life across the prostate cancer continuum.

1

Kratzer TB, et. al. “Prostate cancer statistics, 2025.” CA Cancer J Clin . vol. 75 no. 6 (2025): 485-497. doi:10.3322/caac.70028.

2

Bernard-Terrier A & Beltran H. “Exploring the biology of metastatic hormone-sensitive prostate cancer: on the road to precision medicine.” J Clin Invest . vol. 136 no. 3 (2026):e200920. doi: 10.1172/JCI200920.

3

Leith A, et. al. “Real-World Treatment Patterns in Metastatic Castration-Resistant Prostate Cancer Across Europe (France, Germany, Italy, Spain, and the United Kingdom) and Japan.” Adv Ther . vol. 39 (2022): 2236-2255. doi: 10.1007/s12325-022-02073-w.

4

Huo, X et al. “Predicting Survival in Metastatic Castration-Resistant Prostate Cancer Patients: Development of a Prognostic Nomogram.” Studies in health technology and informatics vol. 323 (2025): 164-168. doi:10.3233/SHTI250070.

About Vir Biotechnology, Inc.

Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes programs for chronic hepatitis delta and multiple PRO-XTEN ® dual-masked T-cell engagers across validated targets in solid tumor indications. Vir Biotechnology also has a preclinical portfolio of programs across a range of oncologic malignancies. Vir Biotechnology routinely posts information that may be important to investors on its website.

Forward-looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “should,” “could,” “may,” “might,” “will,” “plan,” “potential,” “aim,” “expect,” “anticipate,” “promising” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements regarding: the FDA Fast Track designation and potential expedited development for VIR-5500 to address an area of serious unmet need in late-line mCRPC; the therapeutic potential of VIR-5500, both as a monotherapy and as part of combination regimens, to be a treatment for advanced mCRPC (including in early-line) and mHSPC; Vir Biotechnology’s clinical development plans and expectations for VIR-5500, including protocols for and enrollment into ongoing and planned clinical trials (including pivotal Phase 3 trials in 2027), target endpoints and data readouts; Vir Biotechnology’s strategy and plans; and any assumptions underlying any of the foregoing. Many factors may cause differences between current expectations and actual results, including, without limitation: unexpected safety or efficacy data or results observed during clinical studies or in data readouts, including the occurrence of adverse safety events; risks of unexpected costs, delays or other unexpected hurdles; challenges in accessing manufacturing capacity; clinical site activation rates or clinical enrollment rates that are lower than expected; the timing and outcome of Vir Biotechnology’s planned interactions with regulatory authorities, as well as general difficulties in obtaining any necessary regulatory approvals; successful development and/or commercialization of alternative product candidates by Vir Biotechnology’s competitors, as well as changes in expected or existing competition; geopolitical changes or other external factors; and unexpected litigation or other disputes. In light of these risks and uncertainties, the events or circumstances referred to in the forward-looking statements may not occur. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical studies may not be indicative of full results or results from later stage or larger scale clinical studies and do not ensure regulatory approval. The actual results may vary from the anticipated results, and the variations may be material. You are cautioned not to place undue reliance on any scientific data presented or these forward-looking statements, which are based on Vir Biotechnology’s available information, expectations and assumptions as of the date of this press release. Other factors that may cause Vir Biotechnology’s actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Vir Biotechnology’s filings with the U.S. Securities and Exchange Commission, including the section titled “Risk Factors” contained therein. Except as required by law, Vir Biotechnology assumes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Vir Biotechnology has exclusive rights to the universal PRO-XTEN ® masking platform for oncology and infectious disease. PRO-XTEN ® is a trademark of Amunix Pharmaceuticals, Inc., a Sanofi company.

View source version on businesswire.com: https://www.businesswire.com/news/home/20261008428695/en/

Media Contact
Caren Scannell
Director, Communications
cscannell@vir.bio

Investor Contact
Kiki Patel, PharmD
Head of Investor Relations
kpatel@vir.bio

FAQ**

How does the FDA's Fast Track designation for Vir Biotechnology Inc. VIR-5500 enhance its potential to meet the needs of patients with late-line metastatic castration-resistant prostate cancer (mCRPC)?
The FDA's Fast Track designation for Vir Biotechnology Inc.'s VIR-5500 accelerates its development and review process, potentially providing earlier access to treatments for patients with late-line metastatic castration-resistant prostate cancer (mCRPC) who lack effective options.
What are the anticipated benefits of the PRO-XTEN ® masking technology in Vir Biotechnology Inc. VIR-5500 compared to traditional T-cell engagers?
The PRO-XTEN® masking technology in Vir Biotechnology Inc.'s VIR-5500 is anticipated to enhance T-cell engager efficacy by improving tumor targeting, reducing off-tumor toxicity, and potentially increasing therapeutic potency compared to traditional T-cell engagers.
In what ways do the Phase 1 trial results influence the future Phase 3 development plans for Vir Biotechnology Inc. VIR-5500 in 2027?
The Phase 1 trial results for Vir Biotechnology's VIR-5500 will likely inform dosing strategies, identify key safety and efficacy endpoints, and refine target patient populations for Phase 3 trials, ultimately shaping the regulatory and commercial pathways planned for 2027.
What specific patient populations are being targeted in the Phase 1 dose-expansion cohorts for Vir Biotechnology Inc. VIR-5500, and how do these cohorts impact its market potential?
The Phase 1 dose-expansion cohorts for Vir Biotechnology Inc.'s VIR-5500 target patients with chronic hepatitis B virus infections and patients with certain cancer types, potentially enhancing its market potential by addressing significant unmet medical needs in these populations.

**MWN-AI FAQ is based on asking OpenAI questions about Vir Biotechnology Inc. (NASDAQ: VIR).

Vir Biotechnology Inc.

NASDAQ: VIR

VIR Trading

-0.8% G/L:

$13.09 Last:

1,033,066 Volume:

$13.22 Open:

iqst Ad 300

VIR Latest News

$1,054,567,743
108,239,275
0.82%
81
N/A
Biotechnology & Life Sciences
Healthcare
US
San Francisco

Check Your Online Brokerage For VIR

Link Market Wire News to Your X Account

Download The Market Wire News App

Schedule a 30 minute Brand Awareness meeting with Market Wire News